| Management target | Revenue 10.0% |
|---|
| Revenue growth | 2% YoY revenue growth, severely muted by CMO supply constraints. |
|---|---|
| Margins | EBITDA margins improved significantly by 290 basis points to 34%. |
| Demand visibility | Strong demand for shingles vaccine and specialty respiratory products like Nucala. |
| Management confidence | Confident but cautious; focused on pivoting towards specialty and oncology portfolios. |
Growth
PAT grew 10% YoY and EBITDA 11%, driven by higher gross margins and AI-led operational efficiencies.
Outlook
Management maintains an ambitious double-digit growth target for the coming years, supported by 26 clinical trials.
Risks
Continued supply chain fragility and high exposure to NLEM pricing regulations remain key structural risks.
Earnings Call Transcript filed with BSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,815.70
- Market cap
- ₹47,700 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 44.7×Sector 50.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK reported muted 2% revenue growth due to supply chain disruptions at a key CMO, but delivered record-high EBITDA margins of 35% through cost optimization and a shift toward high-margin specialty products.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Investor Presentation: Key Takeaways
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GlaxoSmithKline Pharmaceuticals Q1 FY27 Results: Net Profit ₹237.2 Cr, Up 15.7% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹938.4 Cr (+16.5% YoY) and net profit of ₹237.2 Cr (+15.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹237.2 Cr · +15.7% YoY
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK Pharma Q4 FY26 earnings call highlighting 2% revenue growth, 34% EBITDA margins, and a shift toward an innovation-led specialty portfolio.
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK India delivered double-digit EBITDA and PAT growth for FY26 despite supply disruptions. Performance was bolstered by a transition toward high-margin specialty oncology and adult vaccines, compensating for a muted general medicine segment.